Report Overview
Global Digital Biomarkers in Oncology Clinical Trails Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2026-2033
Digital biomarkers are revolutionizing oncology clinical trials by providing objective, continuous measures of disease progression and treatment response. These biomarkers use advanced technologies like wearable devices, mobile apps, and digital health platforms to collect real-time data on a patient's physiological and behavioral parameters. This approach allows for a more nuanced understanding of cancer and its treatments, potentially leading to more personalized interventions. Integrating digital tools into clinical trials enhances outcome measurements, streamlines data collection, and drives cancer care innovations.
Market Scope
| Metrics | Details |
| CAGR | XX% |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Product Type, Application, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rise in the technological advancements
The global digital biomarkers market in oncology clinical trials is driven by technological advancements such as wearable devices, mobile health apps, and data analytics. These technologies enable real-time monitoring of patient health metrics, providing insights into disease progression and treatment efficacy. The data collection is crucial for assessing new therapies and personalizing patient care. As technology advances, the integration of digital biomarkers in trials becomes more feasible, driving market growth.
Privacy and security concerns
Digital biomarkers, despite their potential, face challenges in data privacy and security due to the collection and storage of sensitive health information. Regulatory requirements like GDPR and HIPAA in the EU and U.S. impose strict guidelines on handling patient information, making compliance complex and costly for organizations. This could potentially hinder the widespread adoption of digital biomarkers in clinical trials.
Market Segmentation Analysis
The global digital biomarkers in oncology clinical trails market is segmented based on product type, application, end-user and region.
The wearable devices from the product type segment accounted for approximately 47.3% of the digital biomarkers in oncology clinical trails market share
The wearable devices from the product type segment accounted for approximately 47.3%. Wearable devices, such as smartwatches, fitness trackers, and biosensors, are revolutionizing the digital biomarkers market for oncology clinical trials. These devices collect real-time data on patients' physiological and behavioral data, such as heart rate, physical activity, sleep patterns, and biochemical markers. This data allows for a more accurate assessment of cancer treatments and disease progression. The integration of wearables in clinical trials also enhances patient engagement and adherence, providing immediate feedback and reminders. This comprehensive view of patients' health status is driving innovation and improving outcomes in oncology research.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the high incidence of cancer, partnerships, advanced healthcare infrastructure, robust research and developments, increased patient engagement and other factors help the region to grow during the forecast period.
For instance, in February 2024, Biofourmis, a global leader in digital health and decentralized clinical trial solutions, announced four new agreements with top pharmaceutical companies, driven by Biofourmis' proven leadership and expertise in digital biomarker development and the strength of its comprehensive, device- and location-agnostic clinical trial solution.
Market Major Players
The major global players in the market include Koneksa Healthcare, Medidata Solutions, Inc, IBM Watson Health, Philips Healthcare, Syneos Health, Oracle Corporation, Pfizer Inc, NantHealth, Medtronic, Curemetrix among others.
Key Developments
June 2026: Boehringer Ingelheim initiated three Phase III precision oncology clinical trials, including the DAREON® and Beamion LUNG-3 programs, using biomarker-informed patient selection to improve treatment precision in difficult-to-treat cancers.
The studies integrate DLL3 and HER2 (ERBB2) biomarker strategies to optimize enrollment, strengthen precision oncology research, and advance targeted therapies into late-stage clinical development.- May 2026: Guardant Health announced 38 oncology abstracts at the ASCO Annual Meeting showcasing advances in its InfinityAI-powered liquid biopsy platform and Guardant360 Liquid CDx.
The data highlighted AI-enabled biomarker discovery, methylation-based tumor profiling, minimal residual disease monitoring, and expanded use of liquid biopsy technologies to support biomarker-guided oncology clinical trials. - January 2026: AstraZeneca announced the acquisition of Modella AI to strengthen AI-driven biomarker discovery and precision oncology clinical development.
The integration of foundation AI models is intended to improve biomarker identification, patient stratification, quantitative pathology, and clinical trial design for oncology programs.
Why Purchase the Report?
- To visualize the global digital biomarkers in oncology clinical trials market segmentation based on product type, application, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of the digital biomarkers in oncology clinical trials market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global digital biomarkers in oncology clinical trials market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
